Browsing by Author "Pir, A"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Retrospective and multicenter analysis of efficacy and safety of ruxolitinib in 176 Turkish patients with myelofibrosis: updated data
    Soyer, N; Ali, R; Turgut, M; Haznedaroglu, I; Yilmaz, F; Aydogdu, I; Pir, A; Karakus, V; Ozgur, G; Kis, C; Ceran, F; Ilhan, G; Ozkan, M; Arslaner, M; Ince, I
  • No Thumbnail Available
    Item
    EFFICACY AND SAFETY OF RUXOLITINIB IN TURKISH PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A MULTICENTER AND RETROSPECTIVE ANALYSIS
    Soyer, N; Turgut, M; Haznedaroglu, I; Yilmaz, F; Aydogdu, I; Pir, A; Karakus, V; Ozgur, G; Kis, C; Ceran, F; Ilhan, G; Ozkan, M; Arslaner, M; Ince, I; Yavasoglu, I
  • No Thumbnail Available
    Item
    Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey
    Soyer, N; Ali, R; Turgut, M; Haznedaroglu, IC; Yilmaz, F; Aydogdu, I; Pir, A; Karakus, V; Özgür, G; Kis, C; Ceran, F; Ilhan, G; Özkan, M; Aslaner, M; Ince, I; Yavasoglu, I; Gediz, F; Sönmez, M; Güvenç, B; Özet, G; Kaya, E; Vural, F; Sahin, F; Töbü, M; Durusoy, R; Saydam, G
    Background/aim: The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. Materials and methods: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated. Results: The median age at ruxolitinib initiation was 62 (28-87) and 100 (56.8%) of all were diagnosed as PMF. Constitutional symptoms were observed in 84.7%. The median initiation dose of ruxolitinib was 30 mg (10-40). Dose change was made in 69 (39.2%) patients. Forty seven (35.6%) and 20 (15.2%) of 132 patients had hematological and nonhematological adverse events, respectively. The mean spleen sizes before and after ruxolitinib treatment were 219.67 +/- 46.79 mm versus 199.49 +/- 40.95 mm, respectively (p < 0.001). There was no correlation between baseline features and subsequent spleen response. Overall survival at 1-year was 89.5% and the median follow up was 10 (1-55) months. We could not show any relationship between survival and reduction in spleen size (p = 0.73). Conclusion: We found ruxolitinib to be safe, well tolerated, and effective in real-life clinical practice in Turkey. Ruxolitinib dose titration can provide better responses in terms of not only clinical benefit but also for long term of ruxolitinib treatment.